3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China
Home-Grown Partnership Pays Dividends
Executive Summary
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
You may also be interested in...
AZ, Junshi Part Ways Amid China IO Commercial Struggle
Multinationals including AstraZeneca are retreating from China’s overcrowded immuno-oncology market but one exception - Pfizer - remains steadfast.
Two More IO Drugs Coming In China As Hengrui, Lee’s File NDAs
The latest immuno-oncology newcomers from Lee’s Pharma and Jiangsu Hengrui will further choke an already crowded field in China if they are approved following recent filings.
China Relaxes Restrictions Amid 'Zero' Severe Shanghai Cases
China is signalling its intention to gradually re-open its borders amid real-world data showing few mild-to-moderate cases progress to severe symptoms. Meanwhile, Pfizer's Paxlovid is seemingly struggling to gain traction amid use guideline changes.